Knight Therapeutics Adósság / tőke
Mi az Knight Therapeutics Adósság / tőke?
A Adósság / tőke az Knight Therapeutics, Inc. - 0.27
Mi a Adósság / tőke meghatározása?
Az adósság és a saját tőke aránya a társasági eszközök finanszírozásához használt saját tőke és adósság viszonylagos arányát jelző pénzügyi arány.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Adósság / tőke a Health Care szektor a TSX-on cégekben a Knight Therapeutics -hoz képest
Mit csinál Knight Therapeutics?
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer. The company also provides Burinex, for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome; PROBUPHINE, to treat opioid addiction; and MOVANTIK for the treatment of opioid-induced constipation. In addition, it offers Vidaza to treat myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven to treat advanced or metastatic breast cancer; Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma; Ladevina to treat multiple myeloma; Zyvalix for metastatic prostate cancer; Karfib to treat relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; AmBisome and Cresemba to treat fungal infection; and Impavido for leishmaniasis. Further, the company provides Ursofalk to treat biliary cirrhosis; Salofalk for ulcerative colitis; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
adósság / tőke -hoz hasonló cégek Knight Therapeutics
- Savara Inc nak Adósság / tőke 0.26 van
- Weyco Inc nak Adósság / tőke 0.27 van
- The Mandhana Retail Ventures nak Adósság / tőke 0.27 van
- Onelife Capital Advisors nak Adósság / tőke 0.27 van
- Petershill Partners PLC nak Adósság / tőke 0.27 van
- Star Cement nak Adósság / tőke 0.27 van
- Knight Therapeutics nak Adósság / tőke 0.27 van
- Mind Cure Health nak Adósság / tőke 0.27 van
- Poly Medicure nak Adósság / tőke 0.27 van
- Staar Surgical Co nak Adósság / tőke 0.27 van
- Smartlink nak Adósság / tőke 0.27 van
- Y-Mabs Therapeutics Inc nak Adósság / tőke 0.27 van
- Sintana nak Adósság / tőke 0.27 van